With the recent legalization of adult-use marijuana in Canada, a major void has been revealed, and that is a lack of scientific research on the health effects of its use – on both the recreational and medical side.
To fill that gap in research, Canadian licensed producer Tetra Bio-Pharma Inc. (TSXV:TBP) (OTC:TBPMF) just partnered up with The Lung Association – Ontario to fund a research program that will investigate various health impacts of cannabis use. The goal of this program will be to better support patients and healthcare providers with evidence-based information.
“It has become very clear that more research is needed to fully understand both the effects of smoking cannabis on your lungs, and the utility of medical cannabis as a viable option for chronic disease pain management and treatment,” says George Habib, President and CEO of The Lung Association – Ontario. “The Lung Association is thrilled to be taking the lead in filling these gaps in knowledge.”
The results from these vital research projects will ensure that there is a larger evidence-base to cite when educating the consumers and healthcare providers about the impact of cannabis consumption on lung health. It will also allow healthcare providers to make more informed decisions on behalf of their patients.
As stated by The American Lung Association, “the health effects of marijuana are determined in large part by how it’s consumed.” It goes without saying that, due to combustion, smoking marijuana is far worse for your lungs than eating an edible:
“Smoke is harmful to lung health. Whether from burning wood, tobacco or marijuana, toxins and carcinogens are released from the combustion of materials. Smoke from marijuana combustion has been shown to contain many of the same toxins, irritants and carcinogens as tobacco smoke.”
Regardless, more research is necessary. The research funded as a result of this collaboration will be driven by The Lung Association – Ontario. It will be fully peer-reviewed and administered in a completely arms-length manner from the funder, Tetra Bio-Pharma. Funding recipients will be announced on March 28, 2019.
“Tetra Bio-Pharma is excited to join forces with The Lung Association – Ontario to expand knowledge on the impact of smoking a cannabinoid-derived product through several pioneering research projects,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “Access to cannabinoid-derived medical therapies is severely limited because of an absence of rigorous safety and efficacy data. We are committed to supporting research excellence to enable innovation but also to establish the evidence that regulators, physicians and insurance companies are waiting for.”
In the meantime, be sure to subscribe to updates here so you never miss an important update.
Get Real-Time Updates from The Daily Marijuana Observer